GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Conba Pharmaceutical Co Ltd (SHSE:600572) » Definitions » Cash And Cash Equivalents

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Cash And Cash Equivalents : ¥2,367 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Conba Pharmaceutical Co Cash And Cash Equivalents?

Zhejiang Conba Pharmaceutical Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥2,244.23 Mil) to Dec. 2023 (¥2,570.01 Mil) but then stayed the same from Dec. 2023 (¥2,570.01 Mil) to Mar. 2024 (¥2,366.98 Mil).

Zhejiang Conba Pharmaceutical Co's annual cash and cash equivalents declined from Dec. 2021 (¥2,573.27 Mil) to Dec. 2022 (¥2,468.03 Mil) but then increased from Dec. 2022 (¥2,468.03 Mil) to Dec. 2023 (¥2,570.01 Mil).


Zhejiang Conba Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Zhejiang Conba Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Conba Pharmaceutical Co Cash And Cash Equivalents Chart

Zhejiang Conba Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,691.20 1,575.06 2,573.27 2,468.03 2,570.01

Zhejiang Conba Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,430.12 2,526.24 2,244.23 2,570.01 2,366.98

Zhejiang Conba Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Zhejiang Conba Pharmaceutical Co  (SHSE:600572) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Zhejiang Conba Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Zhejiang Conba Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Conba Pharmaceutical Co (SHSE:600572) Business Description

Traded in Other Exchanges
N/A
Address
No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
Executives
Hu Ji Qiang Director
Yuan Zhen Xian senior management
Yin Shi Shui Supervisors
Xu Chun Ling senior management
Jin Zu Cheng Directors, senior managers
Ye Jian Feng Supervisors
Ying Chun Xiao Director
Chen Ming Director
Luo Guo Liang Director
Wu Zhong Shi Supervisors
Wang Ru Wei Director
Yang Jun De senior management
Yang Xian Min senior management
Chen Yue Zhong senior management
Li Jian Zhong Supervisors

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Headlines

No Headlines